Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
|
|
HERON THERAPEUTICS, INC. (HRTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/23/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/01/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 07/25/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/24/2023 |
8-K
| Quarterly results |
| 06/30/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/12/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF HERON THERAPEUTICS, INC. Heron Therapeutics, Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware , does hereby certify: FIRST: That, upon the Effective Time, Section A of Article IV of the Certificate of Incorporation of the Corporation shall be amended and restated in its entirety as follows: “A. Authorized Capital. The Corporation is authorized to issue two classes of shares of stock to be designated, respectively, “preferred” and “common.” The total number of shares that the Corporation is authorized to issue is Two Hundred Twenty-Seven Million Five Hundred Thousand . The number of shares of common stock authorized to be issued is Two ...",
"Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer SAN DIEGO, June 12, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the appointment of William Forbes, Pharm.D., as Executive Vice President, Chief Development Officer. In addition, Kimberly Manhard, Heron’s Executive Vice President, Drug Development, has resigned from her position. Dr. Forbes joins Heron’s management team and will be responsible for leading clinical and product development for Heron’s acute care and oncology care franchises. “I am thrilled to welcome Bill to the Heron team a..." |
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates • Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million, Compared to First Quarter Net Product Sales in 2022 • Appointment of Craig Collard as Chief Executive Officer and Jason Grillot as Vice President , Sales and Marketing, of the Acute Care Franchise. SAN DIEGO, May 11, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three months ended March 31, 2023 and highlighted recent corporate updates. First quarter 2023 net product s..." |
|
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/20/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/13/2023 |
SC 13G
| GREAT POINT PARTNERS LLC reports a 5.4% stake in HERON THERAPEUTICS, INC. |
| 04/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Heron Therapeutics Announces New CEO and Board Chairman Craig Collard Appointed CEO Adam Morgan Named Chairman of the Board SAN DIEGO, April 3, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced the appointment of Craig Collard as Chief Executive Officer , effective today. Mr. Collard succeeds Barry Quart, Pharm.D., who has stepped down as CEO and Chairman of the Board. In addition, as part of the leadership change, the Board elected Adam Morgan as Chairman. Mr. Collard brings more than three decades of experience leading innovative pharmaceutical companies through periods of strategic change to deliver growth ..." |
|
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/23/2023 |
8-K
| Quarterly results |
| 03/13/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Heron Therapeutics Announces Centers for Medicare & Medicaid Services Granted Pass-through Payment Status for APONVIETM, Effective April 1, 2023 SAN DIEGO, March 13, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that CMS has approved transitional pass-through status for APONVIE injectable emulsion, which will be established for three years beginning April 1, 2023 under C-code C9145. APONVIE was approved by the U.S. Food and Drug Administration for intravenous use in adults for the prevention of postoperative nausea and vomiting and became commercially available on March 6, 2023. CMS grants pas..." |
|
| 03/06/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/22/2023 |
SC 13D/A
| Rubric Capital Management LP reports a 9.9% stake in Heron Therapeutics, Inc. |
| 02/22/2023 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 3.2% stake in Heron Therapeutics, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 6.6% stake in Heron Therapeutics Inc. |
| 02/06/2023 |
SC 13D
| Rubric Capital Management LP reports a 9.9% stake in Heron Therapeutics, Inc. |
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/31/2023 |
SC 13G/A
| FRANKLIN RESOURCES INC reports a 10% stake in HERON THERAPEUTICS, INC. |
| 01/23/2023 |
SC 13G/A
| JPMORGAN CHASE & CO reports a 5.6% stake in HERON THERAPEUTICS, INC. |
| 01/10/2023 |
SC 13G/A
| STATE STREET CORP reports a 2.2% stake in EXIT FILING HERON THERAPEUTICS INC |
| 01/09/2023 |
8-K
| Quarterly results |
| 12/29/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/08/2022 |
8-K
| Quarterly results |
|
|
|